A commercial-stage psychedelic medicines manufacturer.
Optimi Health Corp. manufactures finished-dose psychedelic medicines at a Health Canada Drug Establishment-licensed facility in British Columbia, and supplies them to authorised psychiatrists in Australia under the TGA Authorised Prescriber Scheme.
Natural extract and synthetic capsule lines. Manufactured under Health Canada Drug Establishment Licence. Supplied to authorised prescribers under the TGA Authorised Prescriber Scheme, Australia.
Product images are for illustrative purposes only and do not reflect final commercial packaging, labeling, or presentation.
Overview.
Optimi Health Corp. (NASDAQ: OPTH · CSE: OPTI) produces finished-dose psychedelic capsule medicines for regulated therapeutic use. The Company operates a Health Canada GMP-compliant facility and holds a Drug Establishment Licence authorizing commercial manufacture, packaging, testing, and international export of controlled drug products.
Active supply into Australia began under the TGA Authorised Prescriber Scheme in 2024. Product is dispensed to patients through authorised prescribers within regulated therapy programs.
The Company is structured to scale into additional jurisdictions as regulatory access develops.
GMP approved. Drug Establishment Licence.
GMP facility
20,000-square-foot Health Canada-inspected facility with a Drug Establishment Licence authorizing commercial manufacture, packaging, testing, and export of controlled drug products.
Qualified Person release
Every batch signed off by a QP per Canadian pharmaceutical regulations. HPLC-MS identity and potency, USP-grade impurity panels, validated stability.
Chain-of-custody export
International narcotic export permits issued per shipment. Controlled-drug chain-of-custody from plant floor to authorised importer to prescribing clinic.